Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory postmenopausal Korean women, ≥ 55 to ≤ 90 years of age at enrollment.~* Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to screening.~* BMD T-score \</= -2.50 at the lumbar spine, total hip or femoral neck.~* At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA.~* Other inclusion criteria may apply.~Exclusion Criteria:~* Subjects with a BMD T-score \</= -4.0 at the lumbar spine, total hip, or femoral neck.~* History of hip fracture.~* Bone disease other than osteoporosis/ or evidence of any other clinically significant disorder, condition/ or disease or significant laboratory abnormalities.~* Known sensitivity or intolerance calcium and vitamin D products.~* Other exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once a month for 6 months.
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).